Your Patient is Diagnosed with Metastatic Pancreatic Cancer: Do You Know the Best Treatment Options?

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: August 16, 2018
Expiration Date: August 16, 2019

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Pancreatic cancer ranks as the third leading cause of cancer-related mortality in the United States, and experts are predicting that it will rise to second place in the next decade. The management of patients with metastatic pancreatic cancer continues to be challenging for clinicians, and few treatment options are available. However, new active areas of research are investigating first- and second-line therapies that may soon expand the treatment armamentarium. In this activity, Dr. Tanios Bekaii-Saab explores two of the latest front-line options being explored in advanced metastatic pancreatic cancer. He also discusses how front-line therapy choices could impact treatment options for second-line therapy.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including medical oncologists, gastroenterologists, oncologists specializing in GI disorders, pharmacists and other allied healthcare professionals who provide care to patients with pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Recognize potential treatment options for patients presenting with locally advanced unresectable pancreatic cancer
  • Evaluate options for patients presenting with advanced metastatic pancreatic cancer based on a patient-centric approach to treatment
  • List currently available options for patients in the community setting, including the availability of clinical trials in progress

Agenda

Your Patient is Diagnosed with Metastatic Pancreatic Cancer: Do You Know the Best Treatment Options? – Tanios Bekaii-Saab, MD, FACP

Instructions for Participation and Credit

This activity is eligible for credit through August 16, 2019. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Tanios Bekaii-Saab, MD, FACP
Professor
Mayo Clinic College of Medicine and Science
Program Co-Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Medical Director, Cancer Clinical Research Office
Section Chief and Vice-Chair
Division of Hematology/Oncology
Mayo Clinic
Phoenix, Arizona

Dr. Tanios Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana. He then completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts. Dr. Bekaii-Saab is a Professor of Medicine at the Mayo Clinic College of Medicine and Science, Leader of the Gastrointestinal Cancer Program at the Mayo Clinic Cancer Center, Medical Director of the Cancer Clinical Research Office, and Vice Chair and Section Chief for Medical Oncology for the Division of Hematology/Oncology in the Department of Internal Medicine at the Mayo Clinic in Phoenix, Arizona.

Dr. Bekaii-Saab has authored or co-authored more than 350 peer reviewed publications, abstracts, and book chapters, including papers in such journals as Lancet Oncology, Journal of Clinical Oncology, JAMA, Journal of the National Cancer Institute, Annals of Oncology, and Clinical Cancer Research.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-021-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Tanios Bekaii-Saab has disclosed no relevant financial relationships.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.